Vor Biopharma (VOR) IPO Opens 122% Higher

Today's IPO for Vor Biopharma (NASDAQ: VOR) opened for trading at $40.02 after pricing 9,828,017 shares of its common stock at a price to the public of $18.00 per share.

Goldman Sachs and Co. LLC, Evercore ISI, Barclays and Stifel are acting as joint book-running managers for the offering.

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering eHSC therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies. By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Inhibrx Biosciences (INBX) Reiterated at Buy by Stifel After Meet with CEO, CFO
• Anthropic plans IPO potentially exceeding SpaceX's $86B record - Bloomberg